NEOGENOMICS INC (NEO) Stock Fundamental Analysis

NASDAQ:NEO • US64049M2098

9.89 USD
-0.12 (-1.2%)
At close: Feb 20, 2026
9.89 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, NEO scores 3 out of 10 in our fundamental rating. NEO was compared to 101 industry peers in the Health Care Providers & Services industry. The financial health of NEO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, NEO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NEO was profitable.
  • In the past year NEO had a positive cash flow from operations.
  • NEO had negative earnings in each of the past 5 years.
  • NEO had negative operating cash flow in 4 of the past 5 years.
NEO Yearly Net Income VS EBIT VS OCF VS FCFNEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.25%, NEO is doing worse than 70.59% of the companies in the same industry.
  • NEO's Return On Equity of -13.54% is on the low side compared to the rest of the industry. NEO is outperformed by 61.76% of its industry peers.
Industry RankSector Rank
ROA -8.25%
ROE -13.54%
ROIC N/A
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
NEO Yearly ROA, ROE, ROICNEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15

1.3 Margins

  • The Gross Margin of NEO (43.46%) is better than 72.55% of its industry peers.
  • NEO's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
NEO Yearly Profit, Operating, Gross MarginsNEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for NEO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NEO Yearly Shares OutstandingNEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NEO Yearly Total Debt VS Total AssetsNEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.56, we must say that NEO is in the distress zone and has some risk of bankruptcy.
  • NEO has a Altman-Z score (1.56) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.41 indicates that NEO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.41, NEO is in the better half of the industry, outperforming 64.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC7.14%
NEO Yearly LT Debt VS Equity VS FCFNEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • NEO has a Current Ratio of 3.91. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
  • NEO has a Current ratio of 3.91. This is amongst the best in the industry. NEO outperforms 89.22% of its industry peers.
  • NEO has a Quick Ratio of 3.62. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
  • NEO has a better Quick ratio (3.62) than 89.22% of its industry peers.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.62
NEO Yearly Current Assets VS Current LiabilitesNEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.00% over the past year.
  • The Earnings Per Share has been decreasing by -3.04% on average over the past years.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.56%

3.2 Future

  • The Earnings Per Share is expected to grow by 49.25% on average over the next years. This is a very strong growth
  • NEO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.72% yearly.
EPS Next Y35.15%
EPS Next 2Y72.06%
EPS Next 3Y62.52%
EPS Next 5Y49.25%
Revenue Next Year9.75%
Revenue Next 2Y9.5%
Revenue Next 3Y9.84%
Revenue Next 5Y9.72%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
NEO Yearly Revenue VS EstimatesNEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NEO Yearly EPS VS EstimatesNEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 82.42, NEO can be considered very expensive at the moment.
  • The rest of the industry has a similar Price/Earnings ratio as NEO.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, NEO is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 60.98, the valuation of NEO can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NEO is on the same level as its industry peers.
  • NEO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 82.42
Fwd PE 60.98
NEO Price Earnings VS Forward Price EarningsNEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEO Per share dataNEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as NEO's earnings are expected to grow with 62.52% in the coming years.
PEG (NY)2.34
PEG (5Y)N/A
EPS Next 2Y72.06%
EPS Next 3Y62.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEOGENOMICS INC

NASDAQ:NEO (2/20/2026, 8:00:01 PM)

After market: 9.89 0 (0%)

9.89

-0.12 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-17
Earnings (Next)04-27
Inst Owners102.56%
Inst Owner Change-4.5%
Ins Owners1.14%
Ins Owner Change0.37%
Market Cap1.28B
Revenue(TTM)N/A
Net Income(TTM)-113.47M
Analysts70.59
Price Target13.77 (39.23%)
Short Float %7.85%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.29%
Min EPS beat(2)31.6%
Max EPS beat(2)40.97%
EPS beat(4)4
Avg EPS beat(4)51.9%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)207.03%
EPS beat(12)12
Avg EPS beat(12)159.81%
EPS beat(16)16
Avg EPS beat(16)125.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.73%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.22%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)2.05%
Revenue beat(16)10
Avg Revenue beat(16)1.77%
PT rev (1m)5.65%
PT rev (3m)34.39%
EPS NQ rev (1m)-2.43%
EPS NQ rev (3m)-0.66%
EPS NY rev (1m)-1.25%
EPS NY rev (3m)-0.77%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-0.11%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 82.42
Fwd PE 60.98
P/S 1.8
P/FCF N/A
P/OCF 93.71
P/B 1.53
P/tB 64.68
EV/EBITDA N/A
EPS(TTM)0.12
EY1.21%
EPS(NY)0.16
Fwd EY1.64%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.11
OCFY1.07%
SpS5.48
BVpS6.48
TBVpS0.15
PEG (NY)2.34
PEG (5Y)N/A
Graham Number4.18
Profitability
Industry RankSector Rank
ROA -8.25%
ROE -13.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.46%
FCFM N/A
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.15%
Cap/Sales 4.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.62
Altman-Z 1.56
F-Score4
WACC7.14%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
EPS Next Y35.15%
EPS Next 2Y72.06%
EPS Next 3Y62.52%
EPS Next 5Y49.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.56%
Revenue Next Year9.75%
Revenue Next 2Y9.5%
Revenue Next 3Y9.84%
Revenue Next 5Y9.72%
EBIT growth 1Y-6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.22%
EBIT Next 3Y41.63%
EBIT Next 5Y28.43%
FCF growth 1Y65.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y158.31%
OCF growth 3YN/A
OCF growth 5Y-21.37%

NEOGENOMICS INC / NEO FAQ

What is the fundamental rating for NEO stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEO.


What is the valuation status for NEO stock?

ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.


How profitable is NEOGENOMICS INC (NEO) stock?

NEOGENOMICS INC (NEO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for NEO stock?

The Earnings per Share (EPS) of NEOGENOMICS INC (NEO) is expected to grow by 35.15% in the next year.